Endocrine therapy for estrogen receptor α (ERα) positive breast cancers employs aromatase inhibitors to block estrogen production and tamoxifen and fulvestrant/Faslodex/ICI 182,780 (ICI) that compete with estrogens for binding to ERα. The gene discussed is ERAS; the disease is breast carcinoma.